Thursday May 31, 1:06 pm Eastern Time
Press Release
SOURCE: Advanced Plant Pharmaceuticals, Inc.
Advanced Plant Pharmaceuticals Inc. - APPI - Submits Quarterly Report
NEW YORK, May 31 /PRNewswire/ -- Advanced Plant Pharmaceuticals, Inc. (OTC Bulletin Board: APPI - news) a company that utilizes whole plants to develop all natural dietary supplements, announces today that the Company has completed and submitted their 10Q filing with the SEC and anticipates the removal of the E from their ticker symbol.
APPI is a company that develops innovative plant formulations and technology for clinical application. APPI has developed ACA TM, which has potential as an immunomodulator in the treatment of patients infected with the HIV virus as well as increasing energy levels in people that suffer from CFS (chronic fatigue syndrome). APPI has also developed Lo-Chol TM, a patented cholesterol reducing dietary supplement proven in clinical studies to reduce total cholesterol up to 58%, reduce triglycerides up to 45%, increase HDL (good cholesterol) up to 60%, and improve the ratio of HDL to LDL up to 46%. APPI's newest product Sinusol TM is a generalized base solution for the development of an extensive line of specialty products related to allergy and sinus conditions. The ingredients include a mixture of gently pH-balanced essential mineral oils that combat the various symptoms related to allergies and sinus disorders including congestions, irritated nasal mucosa, and bacterial and fungal infections. APPI's ``Whole Plant'' Pharmaceutical Grade Process is a trade secret. Utilization of the APPI process converts single or multiple whole plants into all-natural standardized dietary supplements. For more information on APPI, please visit the Company's Web sites at advancedplantpharm.com and appi-cholesterol.com
FORWARD LOOKING STATEMENTS:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.
SOURCE: Advanced Plant Pharmaceuticals, Inc. |
